Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study

X
Trial Profile

QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capsaicin (Primary) ; Pregabalin
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms ELEVATE
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 12 Jul 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
    • 19 Nov 2015 According to an Astellas Pharma media release, results from this trial were published in the European Journal of Pain.
    • 19 Nov 2015 Primary endpoint [Proportion of subjects in each arm who achieve at least 30% decrease in the average pain for the past 24 hours Numeric Pain Rating Scale (NPRS) score from baseline to week 8] has been met, according to an Astellas Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top